SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Drug Delivery: Top Headlines

Compounding firm looks at NDA opportunity for reformulation of Mallinckrodt's H.P. Acthar

Image: iStock/JK1991

23-Mar-2017 - Imprimis Pharmaceuticals says it is evaluating pursuing New Drug Application (NDA) status for some of its product reformulations through the US FDA 505(b)(2) development pathway.

Related news

News in brief

Pulmatrix secures EU patent for dry powder delivery tech

22-Mar-2017 - Pulmatrix Inc has extended its IP portfolio with a European patent for its particle-based drug delivery technology.

update - Epipen manufacturer Meridian Medical Technologies completes investigation

Meda recalls EpiPen batch in Denmark after reports of defects

20-Mar-2017 - Mylan subsidiary Meda has recalled a batch of EpiPens in Denmark after reports some have defective auto-injectors.

Cannabinoid-based chewing gum enrolls patients in Ph II trial

16-Mar-2017 - Axim Biotech has enrolled patients in its Phase II trial for Canchew Plus chewing gum – a delivery method with a “cumulative effect,” says CEO.

Heptares, Daiichi Sankyo to develop small molecules for pain treatment

15-Mar-2017 - Heptares Therapeutics has entered into a drug discovery and licensing agreement with Daiichi Sankyo – providing further validation of the company’s structure-based drug design approach, says CEO.

US FDA orders Scynexis not to start new trials of injectable antifungal

13-Mar-2017 - The US FDA has told Scynexis not to start trials of an injectable formulation of its candidate antifungal Scy-078 after several volunteers developed blood clots during a Phase I study.

Vaxess granted $6m to develop sustained release vaccine patches

07-Mar-2017 - Two Bill & Melinda Gates Foundation grants will be used to develop a polio and measles rubella vaccine delivered through microneedles on a sustained-dermal patch.

Nemus hires Catalent to formulate second chemo-induced nausea drug

06-Mar-2017 - Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.

Drug Delivery: Featured news

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...